Drugs / AR08
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02049164 | Jan → May 2014 | — | Arbor Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01876719 | Jun 2013 → Oct 2014 | attention deficit-hyperactivity disorder | Arbor Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02049164 ↗ |
| Route | Oral | “AR08 QD oral dosing for 14 weeks” NCT02049164 ↗ |